Clinical Trials

Inclusion Criteria:

• Subject is 19 - 79 years of age.
• Willingness and ability to provide informed consent.
• Subject is able to participate fully in all aspects of the study.
• Generally healthly, as determined by study investigators, and not meeting any of the exclusion criteria listed below.
• Is eligible for the 2017-2018 and/or 2018-2019 seasonal influenza vaccine.

Exclusion Criteria: 

• Subject has received this year’s influenza vaccine (2017-2018 or 2018-2019 season; as relevant to each particular season) outside of this study.
• Subject has a history of severe adverse reaction associated with an influenza vaccine.
• Subject is allergic to egg proteins and chicken proteins.
• Subject has a history of Guillain-Barre syndrome.
• Subject has a known or suspected immunodeficiency.
• Subject is on a medication that directly affects the outcome, i.e., treatment with immunosuppressive therapy including:
  • cytotoxic agents or systemic corticosteroids,  systemic corticosteroids for treatment of an acute illness in the last 30 days;
  • a blood product (including immunoglobulin) within 6 months prior to enrollment in the study;
  • anticoagulant therapy (not including anti-platelet drugs such as aspirin and clopidogrel) that would contraindicate intramuscular injection.
• Subject has had a recent (within 6 months) myocardial infarction, fracture, cancer or unplanned hospitalisation.
• Subject weighs ≤ 110 lbs.
• Subject has donated blood in the past 56 days or plans to donate blood at time of study or within 8 weeks after their participation in the study ends weeks after their participation in the study ends.
• Pregnancy (as determined by history or self-report).
• Trying to conceive at time of study or for 28 days after vaccination.
• Transgender women/men will be excluded due to the potential effect of this status on the immune response.
• Note that individuals with stable chronic disease (HTN that is well controlled, T2DM with A1C < 8, CHF if NYHA class I or II) can be included.